From: Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
Mutation
n (%)
L33F
42 (35 %)
I84V
40 (33 %)
L10F
22 (18 %)
I47V
12 (10 %)
V32I
9 (7 %)
V11I
7 (5 %)
I50V
5 (4 %)
T74P
L76V
L89V
I54M
3 (2 %)
I54L
2 (1 %)